0.0291USD-3.00%Mkt Cap: 407871 $P/E: —2d ago
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a ra…
Industry Peers
Diagnostics & Research$226.85BUSDP/E 33.1
$142.58BUSDP/E 38.5
$151.78BUSDP/E 38.6
$47.21BUSDP/E 38.3
$46.86BUSD
$44.35BUSDP/E 39.5
$44.14BUSDP/E 31.4
$41.03BUSDP/E 31.0
$40.83BUSDP/E 105.8
$30.40BUSDP/E 40.4
$30.95BUSDP/E 38.2
$28.55BUSDP/E 32.1
$26.80BUSDP/E 27.4
$26.68BUSDP/E 25.6
$21.92BUSD
$16.98BUSDP/E 35.8
$13.65BUSDP/E 25.3
$13.84BUSD
$13.33BUSDP/E 57.4
$9.55BUSDP/E 19.1
| Headline | Source | Time |
|---|---|---|
Older | ||
BC-Most Active Stocks Nu Holdings Ltd. 50,938,866 16.47 | AAssociated Press Finance | |
ProPhase Labs, Advanced Biological Laboratories Sign Letter of Intent for Reverse Merger ProPhase Labs (PRPH) and Advanced Biological Laboratories said Friday they have signed a letter of i | MMT Newswires | |
 ProPhase Labs Inc (PRPH) Q3 2025 Earnings Call Highlights: Strategic Initiatives and Financial ... ProPhase Labs Inc (PRPH) outlines promising growth strategies amidst cash flow challenges and potential market opportunities. | ||
 ProPhase Labs, Inc. Q3 2025 Earnings Call Summary Moby summary of ProPhase Labs, Inc.'s Q3 2025 earnings call | ||
 Critical Biotech giant files Chapter 11 for 3 COVID labs, eyes Bitcoin treasury as lifeline ProPhase Labs, a biotech firm exploring a crypto treasury strategy, has placed its three units under Chapter 11 bankruptcy. | ||